Extrawell Pharmaceutical Holdings Limited (HKG:0858)
Hong Kong · Delayed Price · Currency is HKD 0.0860
+0.0030 (3.61%)
Jul 18, 2025, 2:45 PM HKT
HKG:0858 Income Statement
Financials in millions HKD. Fiscal year is April - March.
Millions HKD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 55.43 | 59.1 | 72.58 | 73.93 | 78.8 | Upgrade | |
Revenue Growth (YoY) | -6.21% | -18.57% | -1.82% | -6.19% | 1.57% | Upgrade |
Cost of Revenue | 33.56 | 30.32 | 41.43 | 36.37 | 36.24 | Upgrade |
Gross Profit | 21.87 | 28.78 | 31.14 | 37.56 | 42.57 | Upgrade |
Selling, General & Admin | 30.9 | 35.33 | 42.42 | 50.5 | 53.43 | Upgrade |
Operating Expenses | 30.05 | 35.33 | 42.42 | 50.5 | 53.43 | Upgrade |
Operating Income | -8.18 | -6.55 | -11.28 | -12.94 | -10.87 | Upgrade |
Interest Expense | -22.11 | -18.8 | -15.64 | -13.23 | -11.24 | Upgrade |
Interest & Investment Income | 4.98 | 5.67 | 2.99 | 1.08 | 5.17 | Upgrade |
Earnings From Equity Investments | -2.31 | -2.28 | -3.85 | -3.65 | -2.88 | Upgrade |
Other Non Operating Income (Expenses) | -2.57 | -4.74 | -0.27 | -7.76 | 3.82 | Upgrade |
EBT Excluding Unusual Items | -30.19 | -26.69 | -28.05 | -36.5 | -16 | Upgrade |
Gain (Loss) on Sale of Investments | 254.9 | -132.93 | 158.66 | 168.64 | -104.7 | Upgrade |
Gain (Loss) on Sale of Assets | 0.01 | - | - | -0.06 | - | Upgrade |
Other Unusual Items | - | 0.12 | 0.28 | 0.25 | 1.04 | Upgrade |
Pretax Income | 224.72 | -159.51 | 130.9 | 132.33 | -119.66 | Upgrade |
Income Tax Expense | 1.17 | 2.13 | 1.13 | 1.24 | - | Upgrade |
Earnings From Continuing Operations | 223.55 | -161.64 | 129.77 | 131.09 | -119.66 | Upgrade |
Earnings From Discontinued Operations | -0.11 | - | - | - | - | Upgrade |
Net Income to Company | 223.45 | -161.64 | 129.77 | 131.09 | -119.66 | Upgrade |
Minority Interest in Earnings | -0.8 | -1.31 | -0.51 | -0.5 | -1.44 | Upgrade |
Net Income | 222.64 | -162.95 | 129.27 | 130.59 | -121.1 | Upgrade |
Net Income to Common | 222.64 | -162.95 | 129.27 | 130.59 | -121.1 | Upgrade |
Net Income Growth | - | - | -1.01% | - | - | Upgrade |
Shares Outstanding (Basic) | 2,390 | 2,390 | 2,390 | 2,390 | 2,390 | Upgrade |
Shares Outstanding (Diluted) | 3,290 | 2,390 | 3,290 | 3,290 | 2,390 | Upgrade |
Shares Change (YoY) | 37.66% | -27.36% | - | 37.66% | -27.36% | Upgrade |
EPS (Basic) | 0.09 | -0.07 | 0.05 | 0.05 | -0.05 | Upgrade |
EPS (Diluted) | 0.07 | -0.07 | 0.04 | 0.04 | -0.05 | Upgrade |
EPS Growth | - | - | 0.78% | - | - | Upgrade |
Free Cash Flow | - | -4.89 | -5.44 | -11.39 | -1.57 | Upgrade |
Free Cash Flow Per Share | - | -0.00 | -0.00 | -0.00 | -0.00 | Upgrade |
Gross Margin | 39.46% | 48.70% | 42.91% | 50.80% | 54.02% | Upgrade |
Operating Margin | -14.76% | -11.09% | -15.54% | -17.51% | -13.79% | Upgrade |
Profit Margin | 401.67% | -275.73% | 178.11% | 176.65% | -153.67% | Upgrade |
Free Cash Flow Margin | - | -8.28% | -7.49% | -15.41% | -2.00% | Upgrade |
EBITDA | -0.9 | 0.73 | -4.63 | -6.4 | -4.9 | Upgrade |
EBITDA Margin | -1.62% | 1.24% | -6.38% | -8.66% | -6.22% | Upgrade |
D&A For EBITDA | 7.29 | 7.29 | 6.65 | 6.54 | 5.97 | Upgrade |
EBIT | -8.18 | -6.55 | -11.28 | -12.94 | -10.87 | Upgrade |
EBIT Margin | -14.76% | -11.09% | -15.54% | -17.51% | -13.79% | Upgrade |
Effective Tax Rate | 0.52% | - | 0.86% | 0.94% | - | Upgrade |
Updated Dec 17, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.